Revamilast ( DrugBank: Revamilast )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
46悪性関節リウマチ2

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01430507
(ClinicalTrials.gov)
September 20117/9/2011A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid ArthritisA Phase IIb, 12 Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Revamilast in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to MethotrexateRheumatoid ArthritisDrug: Revamilast;Drug: Placebo ComparatorGlenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals S.A.Completed18 Years65 YearsBoth406Phase 2India;Philippines;Poland;Sri Lanka;United Kingdom
2EUCTR2011-000107-40-GB
(EUCTR)
16/06/201110/03/2011A 12 weeks study to evaluate effect of revamilst in addition tomethotrexate in rheumatiod arthritis patients.A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumatoid Arthritis who have had an inadequate response to Methotrexate. Rheumatoid Arthritis
MedDRA version: 15.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Revamilast
Product Code: GRC 4039
INN or Proposed INN: Revamilast
Product Name: Revamilast
Product Code: GRC 4039
INN or Proposed INN: Revamilast
Product Name: Revamilast
Product Code: GRC 4039
INN or Proposed INN: Revamilast
Glenmark Pharmaceuticals SANULLNot RecruitingFemale: yes
Male: yes
406Phase 2Philippines;Poland;Sri Lanka;United Kingdom;India